eyenovia-logo 3

Investor Relations

Investor Relations

Corporate Profile

Eyenovia is a late-stage ophthalmic biopharmaceutical company developing breakthrough treatments for front and back-of-the-eye diseases, which are made possible by the company’s transformative, high precision ophthalmic delivery platform. Eyenovia’s pipeline is currently focused on the development of four programs including myopia (nearsightedness) progression, glaucoma and other eye diseases

Presentation & Investor Materials

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News Releases
05/13/20
Eyenovia Reports First Quarter 2020 Financial Results
05/06/20
Eyenovia Announces Conference Call and Webcast for First Quarter 2020 Financial Results
03/25/20
Eyenovia Reports Fourth Quarter and Full Year 2019 Financial Results
Upcoming Events
There are currently no events scheduled.